Epithelial Thymic Neoplasms

  • Mayndra Mychelle Landgraf
  • Daiane Pereira Guimarães
  • Hakaru Tadokoro
  • Ramon Andrade De MelloEmail author


The thymic epithelial tumors represent a heterogeneous group of thoracic cancers that originate in the thymus and are in the anterior mediastinum (de Jong WK, Blaauwgeers JL, Schaapveld M et al. Eur J Cancer 44:123–130, 2008). They are classified according to the World Health Organization (WHO) in Thymoma and Thymic Carcinoma (Marx A, Chan JK, Coindre JM et al. J Thorac Oncol 10:1383–1395, 2015). Thymomas may spread locally, but thymic carcinomas are much more aggressive (Proceedings of the First International Conference on Thymic Malignancies. August 20–21, 2009. Bethesda, Maryland, USA. J Thorac Oncol 2010;5:S259–S370, 2009).


Oncology Chemotherapy Thoracic oncology 


  1. 1.
    de Jong WK, Blaauwgeers JL, Schaapveld M et al (2008) Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 44:123–130CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Marx A, Chan JK, Coindre JM et al (2015) The 2015 World Health Organization Classification of Tumors of the Thymus: continuity and changes. J Thorac Oncol 10:1383–1395CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Proceedings of the First International Conference on Thymic Malignancies. August 20–21, 2009. Bethesda, Maryland, USA. J Thorac Oncol 2010;5:S259–S370Google Scholar
  4. 4.
    Rashid OM, Cassano AD, Takabe K (2013) Thymic neoplasm: a rare disease with a complex clinical presentation. J Thorac Dis 5:173–183PubMedPubMedCentralGoogle Scholar
  5. 5.
    Detterbeck FC, Zeeshan A (2013) Thymoma: current diagnosis and treatment. Chin Med J 126:2186–2191PubMedPubMedCentralGoogle Scholar
  6. 6.
    Huang J, Rizk NP, Travis WD et al (2009) Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg 138:26–31CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Eng TY, Fuller CD, Jagirdar J et al (2004) Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 59:654–664CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Safieddine N, Liu G, Cuningham K et al (2014) Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma. J Thorac Oncol 9:1018CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Litvak AM, Woo K, Hayes S et al (2014) Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. J Thorac Oncol 9:1810–1815CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Detterbeck FC, Parsons AM (2011) Management of stage I and II thymoma. Thorac Surg Clin 21:59–67, vi–viiCrossRefGoogle Scholar
  11. 11.
    Moran CA, Suster S (2008) Thymic carcinoma: current concepts and histologic features. Hematol Oncol Clin North Am 22:393–407CrossRefGoogle Scholar
  12. 12.
    DeVita VT Jr, Lawrence TS, Rosenberg SA. Cancer: principles and practice of oncology, 10th ednGoogle Scholar
  13. 13.
    Suster S, Rosai J (1991) Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 67:1025–1032CrossRefGoogle Scholar
  14. 14.
    Bernard C, Frih H, Pasquet F et al (2016) Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev 15:82–92CrossRefGoogle Scholar
  15. 15.
    Ruffini E, Venuta F (2014) Management of thymic tumors: a European perspective. J Thorac Dis 6(Suppl 2):S228–S237PubMedPubMedCentralGoogle Scholar
  16. 16.
    Evoli A, Lancaster E (2014) Paraneoplastic disorders in thymoma patients. J Thorac Oncol 9(Suppl 2):S143–S147CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Blossom GB, Ernstoff RM, Howells GA et al (1993) Thymectomy for myasthenia gravis. Arch Surg 128:854–862CrossRefGoogle Scholar
  18. 18.
    Marx A, Hohenberger P, Hoffmann H et al (2010) The autoimmune regulator AIRE in thymoma biology: autoimmunity and beyond. J Thorac Oncol 5(Suppl 4):S266–S272CrossRefGoogle Scholar
  19. 19.
    Girard N, Ruffini E, Marx A et al (2015) Thymic epitelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Supplement 5):v40–v55CrossRefGoogle Scholar
  20. 20.
    NCCN. Clinical practice guidelines in oncology. Thymic malignancies. V.1.2017. (Date last accessed 16 Nov 2017)
  21. 21.
    Falkson CB, Bezjak A, Darling G et al (2009) The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 4:911–919CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Morrissey B, Adams H, Gibbs AR et al (1993) Percutaneous needle biopsy of the mediastinum: review of 94 procedures. Thorax 48:632–637CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Carter BW, Marom EM, Detterbeck FC (2014) Approaching the patient with an anterior mediastinal mass: a guide for clinicians. J Thorac Oncol 9(Suppl 2):S102–S109CrossRefGoogle Scholar
  24. 24.
    Kaira K, Endo M, Abe M et al (2010) Biologic correlation of 2-[18F]-fluoro-2-deoxy-D- glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 28:3746–3753CrossRefGoogle Scholar
  25. 25.
    Fukai I, Funato Y, Mizuno T et al (1991) Distribution of thymic tissue in the mediastinal adipose tissue. J Thorac Cardiovasc Surg 101:1099–1102PubMedGoogle Scholar
  26. 26.
    Wang H, Sima CS, Beasley MB et al (2014) Classification of thymic epithelial neoplasms is still a challenge to thoracic pathologists: a reproducibility study using digital microscopy. Arch Pathol Lab Med 138:658–663CrossRefGoogle Scholar
  27. 27.
    Kondo K, Yoshizawa K, Tsuyuguchi M et al (2004) WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 77:1183–1188CrossRefGoogle Scholar
  28. 28.
    Suster S, Moran CA (2006) Thymoma classification: current status and future trends. Am J Clin Pathol 125:542–554CrossRefGoogle Scholar
  29. 29.
    Hsu CP, Chan CY, Chen CL et al (1994) Thymic carcinoma: ten years’ experience in twenty patients. J Thorac Cardiovasc Surg 107:615–620PubMedGoogle Scholar
  30. 30.
    Marx A, Ströbel P, Badve SS et al (2014) ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol 9:596–611CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ionescu DN, Sasatomi E, Ciepley K et al (2005) Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 103:630–636CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Strobel P, Hartmann M, Jakob A et al (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625–2626CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Masaoka A (2010) Staging system of thymoma. J Thorac Oncol 5:S304–S312CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Detterbeck F, Youssef S, Ruffini E, Okumura M (2011) A review of prognostic factors in thymic malignancies. J Thorac Oncol 6(Suppl 3):S1698–S1704CrossRefGoogle Scholar
  35. 35.
    Detterbeck FC, Stratton K, Giroux D et al (2014) The IASLC/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 9(Suppl 2):S65–S72CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ruffini E, Detterbeck F, Van Raemdonck D et al (2014) Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg 46:361–368CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr (2011) Standard outcome measures for thymic malignancies. J Thorac Oncol 6(Suppl 3):S1691–S1697CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ried M, Potzger T, Sziklavari Z et al (2014) Extended surgical resections of advanced thymoma Masaoka stages III and IVa facilitate outcome. Thorac Cardiovasc Surg 62:161–168PubMedPubMedCentralGoogle Scholar
  39. 39.
    Bhora FY, Chen DJ, Detterbeck FC et al (2014) The ITMIG/IASLC thymic epithelial tumors staging project: a proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors. J Thorac Oncol 9(Suppl 2):S88–S96CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Detterbeck FC, Moran C, Huang J et al (2011) Which way is up? Policies and procedures for surgeons and pathologists regarding resection specimens of thymic malignancy. J Thorac Oncol 6(Suppl 3):S1730–S1738CrossRefGoogle Scholar
  41. 41.
    Hamaji M, Ali SO, Burt BM (2014) A meta-analysis of surgical versus nonsurgical management of recurrent thymoma. Ann Thorac Surg 98:748CrossRefGoogle Scholar
  42. 42.
    Utsumi T, Shiono H, Kadota Y et al (2009) Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer 115:5413–5420CrossRefGoogle Scholar
  43. 43.
    Korst RJ, Kansler AL, Christos PJ, Mandal S (2009) Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 87:1641–1647CrossRefGoogle Scholar
  44. 44.
    Chen YD, Feng QF, Lu HZ et al (2010) Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys 78:1400–1406CrossRefGoogle Scholar
  45. 45.
    Weksler B, Shende M, Nason KS et al (2012) The role of adjuvant radiation therapy for resected stage III thymoma: a population-based study. Ann Thorac Surg 93:1822–1828CrossRefGoogle Scholar
  46. 46.
    Gomez D, Komaki R, Yu J et al (2011) Radiation therapy definitions and reporting guidelines for thymic malignancies. J Thorac Oncol 6(Suppl 3):S1743–S1748CrossRefGoogle Scholar
  47. 47.
    Omasa M, Date H, Sozu T et al (2015) Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study. Cancer 121:1008–1016CrossRefGoogle Scholar
  48. 48.
    Kim ES, Putnam JB, Komaki R et al (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44:369–379CrossRefGoogle Scholar
  49. 49.
    Hassan M, Seoud DE (2009) Multimodality treatments in locally advanced stage thymomas. Hematol Oncol Stem Cell Ther 2:340–344CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Loehrer PJ Sr, Chen M, Kim K et al (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 15:3093–3099CrossRefGoogle Scholar
  51. 51.
    Korst RJ, Bezjak A, Blackmon S et al (2014) Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg 147:36–44CrossRefGoogle Scholar
  52. 52.
    Wright CD, Choi NC, Wain JC et al (2008) Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 85:385–389CrossRefGoogle Scholar
  53. 53.
    Attaran S, McCormack D, Pilling J, Harrison-Phipps K (2012) Which stages of thymoma benefit from adjuvant chemotherapy post-thymectomy? Interact Cardiovasc Thorac Surg 15:273–275CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Loehrer PJ Sr, Kim K, Aisner SC et al (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12:1164–1168CrossRefGoogle Scholar
  55. 55.
    Lemma GL, Lee JW, Aisner SC et al (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060–2065CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Giaccone G, Ardizzoni A, Kirkpatrick A et al (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14:814–820CrossRefGoogle Scholar
  57. 57.
    Loehrer PJ Sr, Jiroutek M, Aisner S et al (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91:2010–2015CrossRefGoogle Scholar
  58. 58.
    Palmieri G, Merola G, Federico P et al (2010) Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 21:1168–1172CrossRefGoogle Scholar
  59. 59.
    Loehrer PJ, Yiannoutsos CT, Dropcho S et al (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 24(Suppl 18):abstr 7079Google Scholar
  60. 60.
    Lara PN Jr, Bonomi PD, Faber LP (1996) Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest 110:1115–1117CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Loehrer PJ Sr, Wang W, Johnson DH et al (2004) Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 22:293–299CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Koizumi T, Takabayashi Y, Yamagishi S et al (2002) Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 25:266–268CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Rajan A, Girard N, Marx A (2014) State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol 9(Suppl 2):S131–S136CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Thomas A, Rajan A, Berman A et al (2015) Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 16:177–186CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Girard N (2012) Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther 12:685–695CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Salter JT, Lewis D, Yiannoutsos C et al (2008) Imatinib for the treatment of thymic carcinoma. J Clin Oncol 26(15s suppl):abstr 8116CrossRefGoogle Scholar
  67. 67.
    Zucali PA, De Pas TM, Palmieri G et al (2014) Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 32(5s suppl):abstr 7527CrossRefGoogle Scholar
  68. 68.
    Haniuda M, Kondo R, Numanami H et al (2001) Recurrence of thymoma: clinicopathological features, re-operation, and outcome. J Surg Oncol 78:183CrossRefGoogle Scholar
  69. 69.
    Welsh JS, Wilkins KB, Green R et al (2000) Association between thymoma and second neoplasms. JAMA 283:1142CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mayndra Mychelle Landgraf
    • 1
  • Daiane Pereira Guimarães
    • 2
  • Hakaru Tadokoro
    • 3
  • Ramon Andrade De Mello
    • 4
    • 5
    Email author
  1. 1.Department of Medical Oncology, São Paulo University HospitalFederal University of São PauloSão PauloBrazil
  2. 2.Division of Medical OncologyFederal University of São Paulo – UNIFESPSão PauloBrazil
  3. 3.Division of Medical Oncology, Escola Paulista de MedicinaFederal University of São PauloSão PauloBrazil
  4. 4.Division of Medical OncologyFederal University of São Paulo (UNIFESP) & Hospital Israelita Albert EinsteinSão PauloBrazil
  5. 5.Department of Biomedical Sciences and MedicineUniversity of AlgarveFaroPortugal

Personalised recommendations